You are herePharma News

Pharma News


Mauna Kea Technologies inventor of Cellvizio receives Mexican approval

Mauna Kea Technologies, inventor of Cellvizio, the multidisciplinary confocal laser endomicroscopy platform, has received regulatory approval from COFEPRIS (Comisión Federal Para la Protección contra Riesgos Sanitarios), the Mexican health authority, for the commercialization of Cellvizio.. Mauna Kea Technologies is now able to implement its marketing strategy with its partner, Endomédica, a company specialized in the fields of interventional endoscopy, gastroenterology, urology and surgery since 1986.

Syneron Medical's PicoWay picosecond laser approved by USFDA to treat pigmented lesions

Syneron Medical Ltd. (NASDAQ: ELOS), a global market leader in the aesthetic medical device marketplace, announced today that the PicoWay® picosecond laser received U.S. Food and Drug Administration (FDA) clearance for the treatment of pigmented lesions.

Piramal Imaging pleased to support study on assessing value of PET scans in Alzheimer’s disease and Dementia Diagnosis

Piramal Imaging is honoured to announce it will provide funding and support, along with other industry partners, for a major clinical study titled, "Imaging Dementia – Evidence for Amyloid Scanning" (IDEAS). The trial is designed to evaluate the impact of positron emission tomography (PET) scanning of beta-amyloid deposits in the diagnosis of Alzheimer’s disease (AD) and Dementia in a defined patient population.

For heart disease research Chennai based Lifeline Hospital join hands with Russia

The Chennai based Frontier Lifeline Hospital (FLL) and The Institute for Atherosclerosis Research, Moscow in Russia,  merge for a collaborative research agreement to study the ‘genetic similarities causing heart diseases in Russians & Indians’.

Merck Collaborates with Maharashtra University to Build Diabetes and Hypertension Healthcare Capacity India

Merck, a leading company for innovative and top-quality high-tech products in healthcare, life science and performance materials, in collaboration with Maharashtra University of Health Sciences and Directorate of Medical Education & Research is introducing European Accredited Clinical Diabetes management for more than 5000 medical students in 18 medical colleges of Maharashtra University as part of Merck Capacity Advancement Program (CAP) in Asia.

Lupin introduce Zaxine in Canada for liver disease treatment

Pharma Major Lupin’s Canadian subsidiary, Lupin Pharma Canada has launched its first Brand product Zaxine under a strategic licensing agreement with the North Carolina based GI specialty company Salix Pharmaceuticals Inc. The agreement grants Lupin exclusive rights to promote, distribute and market Zaxine in the Canada.

AstraZeneca's selumetinib get US FDA orphan drug status for uveal melanoma treatment

AstraZeneca, a global, innovation-driven biopharmaceutical business,  announced that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation for the MEK inhibitor selumetinib, for the treatment of uveal melanoma.

Health Ministry launched new system to take action related to non-availability and overcharging of medicines

All essential medicines specified in the National List of Essential Medicines, 2011 (NLEM) are included in the First Schedule of DPCO, 2013 and are under price control. However, Life saving drugs are not defined in the Drugs (Price Control) Order, 2013.

Siemens' Healthcare launch new ACUSON S2000 Helx ultrasound system for management of liver diseases

Liver disease is common problem.  According to a study, one in 5 Indians is affected by liver disease. In Mumbai alone, nearly 2000 patients die annually from liver failure.

Sandoz generic Copaxone get US FDA approval for to treat relapsing forms of multiple sclerosis

Sandoz, a global leader in generic pharmaceuticals and a  subsidiary of Novartis, has received approval from the US Food and Drug Administration (FDA) for Glatopa. Glatopa is the first FDA-approved, substitutable generic version of Copaxone® 20mg, a treatment for relapsing forms of multiple sclerosis. Sandoz, together with Momenta, is proud to be the first company to receive FDA approval for a substitutable generic version of this important therapy.